In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK’s Big Push To Maintain Its Respiratory Reign

Executive Summary

GlaxoSmithKline is counting on new products like Breo Ellipta and Anoro Ellipta to extend its legacy in respiratory disease beyond Advair Diskus, which could face generic competition within the next five years. But GSK may need to wage a battle on the reimbursement front before it can claim commercial success – a challenge highlighted by Express Scripts’ unexpected decision to put Advair and Breo on its not covered list for 2014.

Advertisement

Related Content

GSK Gets New Start For Breo With FDA Approval In Asthma
Head Of The Class: A Star Stands Out Among 2014 Drug Launches
Transforming A European Mid-Sized Pharma: An Interview With Almirall President Jorge Gallardo
GSK Reveals Big Changes As 2015 Growth Prospects Fizzle
GSK’s Breo Ellipta Marches Forward For Asthma, Efficacy Undistinguished From Advair
Advair Generics Likely Lucrative Product For Few That Can Clear High Bar
GSK’s Breo Ellipta Approved With COPD Airflow Obstruction, Exacerbation Claims
COPD Market Snapshot: New Products, Limited Differentiation
Novartis Once-Daily COPD Combo Safe, Effective And Ready For Filing – Everywhere But In The U.S.
Reading Into Pfizer's Changes: First Steps For New CEO

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003957

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel